Investigating the effect of TRPV4 inhibition on pulmonary-vascular barrier permeability following segmental endotoxin challenge
Pulmonary Pharmacology & Therapeutics · 2020-10 · 64 · 101977
DOI: 10.1016/j.pupt.2020.101977 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Pulmonary Pharmacology & Therapeutics, 2020-10. Verfasst von Sarah Mole und 12 weiteren Autor:innen. Beteiligte Einrichtung: GlaxoSmithKline, Gunnells Wood Road, Stevenage, UK. Electronic address: sarah.x.mole@gsk.com. Hauptthemen laut MEDLINE: Capillary Permeability, TRPV Cation Channels. Die Arbeit wurde bisher 20-mal zitiert (Crossref) und nennt 34 Literaturangaben. Gefördert von: Biomedical Advanced Research and Development Authority.
Abstract (Originalsprache)
BACKGROUND: Acute Respiratory Distress Syndrome (ARDS) is associated with increased pulmonary-vascular permeability. In the lung, transient receptor potential vanilloid 4 (TRPV4), a Ca2+-permeable cation channel, is a regulator of endothelial permeability and pulmonary edema. We performed a Phase I, placebo-controlled, double-blind, randomized, parallel group, proof-of-mechanism study to investigate the effects of TRPV4 channel blocker, GSK2798745, on pulmonary-vascular barrier permeability using a model of lipopolysaccharide (LPS)-induced lung inflammation. METHODS: Healthy participants were randomized 1:1 to receive 2 single doses of GSK2798745 or placebo, 12 h apart. Two hours after the first dose, participants underwent bronchoscopy and segmental LPS instillation. Total protein concentration and neutrophil counts were measured in bronchoalveolar lavage (BAL) samples collected before and 24 h after LPS challenge, as markers of barrier permeability and inflammation, respectively. The primary endpoint was baseline adjusted total protein concentration in BAL at 24 h after LPS challenge. A Bayesian framework was used to estimate the posterior probability of any percentage reduction (GSK2798745 relative to placebo). Safety endpoints included the incidence of adverse events (AEs), vital signs, 12-lead electrocardiogram, clinical laboratory and haematological evaluations, and spirometry. RESULTS: Forty-seven participants were dosed and 45 completed the study (22 on GSK2798745 and 23 on placebo). Overall, GSK2798745 was well tolerated. Small reductions in mean baseline adjusted BAL total protein (~9%) and neutrophils (~7%) in the LPS-challenged segment were observed in the GSK2798745 group compared with the placebo group; however, the reductions did not meet pre-specified success criteria of at least a 95% posterior probability that the percentage reduction in the mean 24-h post LPS BAL total protein level (GSK2798745 relative to placebo) exceeded zero. Median plasma concentrations of GSK2798745 were predicted to inhibit TRPV4 on lung vascular endothelial cells by ~70-85% during the 24 h after LPS challenge; median urea-corrected BAL concentrations of GSK2798745 were 3.0- to 8.7-fold higher than those in plasma. CONCLUSIONS: GSK2798745 did not affect segmental LPS-induced elevation of BAL total protein or neutrophils, despite blood and lung exposures that were predicted to be efficacious. CLINICALTRIALS. GOV IDENTIFIER: NCT03511105.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- GlaxoSmithKline, Gunnells Wood Road, Stevenage, UK. Electronic address: sarah.x.mole@gsk.com.
- GlaxoSmithKline, 1250 South Collegeville Road, Collegeville, PA, 19426, USA.
- GlaxoSmithKline, Stockley Park, West Uxbridge, Middlesex, UB11 1BT, UK.
- GlaxoSmithKline, Gunnells Wood Road, Stevenage, UK.
- Fraunhofer-Institut Fuer Toxikologie und Experimentelle Medizin [ITEM], Nikolai-Fuchs-Straße 1, 30625, Hannover, Germany.
- Fraunhofer-Institut Fuer Toxikologie und Experimentelle Medizin [ITEM], Nikolai-Fuchs-Straße 1, 30625, Hannover, Germany; Hannover Medical School and German Centre for Lung Research, Medizinische Hochschule Hannover OE6…
Förderung
- Biomedical Advanced Research and Development Authority
Zitieren
APA
Mole, S., Harry, A., Fowler, A., Hotee, S., Warburton, J., Waite, S., Beerahee, M., Behm, D. J., Badorrek, P., Müller, M., Faulenbach, C., Lazaar, A. L., & Hohlfeld, J. M. (2020). Investigating the effect of TRPV4 inhibition on pulmonary-vascular barrier permeability following segmental endotoxin challenge. Pulmonary Pharmacology & Therapeutics, 64, 101977. https://doi.org/10.1016/j.pupt.2020.101977
Vancouver
Mole S, Harry A, Fowler A, Hotee S, Warburton J, Waite S, et al. Investigating the effect of TRPV4 inhibition on pulmonary-vascular barrier permeability following segmental endotoxin challenge. Pulmonary Pharmacology & Therapeutics. 2020;64:101977. doi:10.1016/j.pupt.2020.101977
BibTeX
@article{Mole2020,
author = {Mole, Sarah and Harry, Anya and Fowler, Andy and Hotee, Sarah and Warburton, Joseph and Waite, Sarah and Beerahee, Misba and Behm, David J and Badorrek, Philipp and Müller, Meike and Faulenbach, Cornelia and Lazaar, Aili L and Hohlfeld, Jens M},
title = {Investigating the effect of TRPV4 inhibition on pulmonary-vascular barrier permeability following segmental endotoxin challenge},
journal = {Pulmonary Pharmacology & Therapeutics},
year = {2020},
volume = {64},
pages = {101977},
doi = {10.1016/j.pupt.2020.101977}
}
EUVIMED